Consejo Superior de Investigaciones Científicas-ko ikertzaileekin lankidetzan egindako argitalpenak (32)

2022

  1. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

  2. Genomic mapping of copy number variations influencing immune response in breast cancer

    Frontiers in Oncology, Vol. 12

  3. HER3 in cancer: from the bench to the bedside

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  4. Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21

    Cancer Research, Vol. 82, Núm. 3, pp. 447-457

  5. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. Generation of antibody‐drug conjugate resistant models

    Cancers, Vol. 13, Núm. 18

  3. Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer

    Cancers, Vol. 13, Núm. 16

  4. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  5. Mapping of genomic vulnerabilities in the post-translational ubiquitination, sumoylation and neddylation machinery in breast cancer

    Cancers, Vol. 13, Núm. 4, pp. 1-23

  6. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  7. PDCD4 limits prooncogenic neuregulin-ErbB signaling

    Cellular and Molecular Life Sciences, Vol. 78, Núm. 4, pp. 1799-1815

  8. Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer

    Frontiers in Oncology, Vol. 11

  9. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine

    Frontiers in Oncology, Vol. 10

  2. HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies

    EMBO Molecular Medicine, Vol. 12, Núm. 5

  3. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

2018

  1. Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer

    International Journal of Oncology, Vol. 53, Núm. 1, pp. 113-123

  2. Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: Understanding clinical trial results

    Oncotarget, Vol. 9, Núm. 61, pp. 31915-31919